Arvelle Therapeutics

Developer of small molecule therapies for the treatment of CNS disorders

placeZug, Canton Of Zug, Switzerland calendar_todayFounded 2019 groups60 employees language arvelletx.com

Social engagement

Social engagement: 7.1K social following, 8 posts in the last 12 months — below the industry typical range.

Investor mix

11 investors on record; lead investors include Andera Partners, NovaQuest Capital Management, Life Sciences Partners, BRV Capital Management; 7 have since exited.

Investor typeCountShare
Venture capital327%
Private equity545%
Other / undisclosed327%

Recent activity

29 Jun 2026
Event
12th Congress of the European Academy of Neurology (EAN)
27 Jan 2026
Leadership hire
CEO
27 Oct 2025
Event
6th SFCNS Congress
Coming soon